Literature DB >> 3016899

Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA.

M Stevenson, B Volsky, M Hedenskog, D J Volsky.   

Abstract

Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, has the ability to transform human B lymphocytes. No other cell type has been experimentally transformed by EBV, either by intact virions or naked viral DNA and subgenomic fragments. Two immortalized human T-lymphoblastoid cell lines have now been established by transfecting cord blood lymphocytes with purified B95-8 viral DNA enclosed in fusogenic Sendai virus envelopes (RSVE) and then exposing the cells to EBV from a P3HR-1 cell subclone. One of these lines, which has been fully characterized, is termed HBD-1. This line is positive for EBV DNA and expresses surface OKT11, OKT4, and Tac receptors, but not M-1, mu immunoglobulin chains, EBV receptors, or B-1 surface markers. The cells contain fully rearranged T-cell receptor genes and germline immunoglobulin genes. The karyotype of the cells is normal, they do not require interleukin-2 for growth, and do not contain human T-lymphotropic virus type I. However, the HBD-1 cells contain incomplete EBV genomes and express several EBV-determined antigens, including the early antigen type D, membrane antigens, but not EBV-determined nuclear antigen (EBNA). This association of the EBV genome with permanently growing hematopoietic cells of non B-cell lineage should prove useful in studies on the mechanism of EBV-mediated cell transformation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016899     DOI: 10.1126/science.3016899

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  12 in total

1.  Epstein-Barr viral genome in lymph nodes from patients with Hodgkin's disease may not be specific to Reed-Sternberg cells.

Authors:  A Masih; D Weisenburger; M Duggan; J Armitage; R Bashir; D Mitchell; R Wickert; D T Purtilo
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

2.  Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone.

Authors:  J E Hambor; C A Hauer; H K Shu; R K Groger; D R Kaplan; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

3.  Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).

Authors:  J D Fingeroth; M L Clabby; J D Strominger
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

4.  Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus.

Authors:  C Rooney; J G Howe; S H Speck; G Miller
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

5.  Functional characterization of human T cells immortalized by oncogene transfection.

Authors:  S Alam; Y Katakura; H Yoshida; E H Kim; S Shirahata
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

6.  Enteropathy-associated T-cell lymphoma in a renal transplant patient with evidence of Epstein-Barr virus involvement.

Authors:  B Borisch; I Hennig; F Horber; K Bürki; J Laissue
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Immortalization of human T lymphocytes by oncogenes.

Authors:  F Okano; H Tachibana; K Akiyama; S Shirahata; H Murakami
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Downregulation of cell surface molecules during noncytopathic infection of T cells with human immunodeficiency virus.

Authors:  M Stevenson; X H Zhang; D J Volsky
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

9.  A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas.

Authors:  S J Hamilton-Dutoit; G Pallesen
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

10.  Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association.

Authors:  I Vorechovsky; J Litzman; J Lokaj; P Hausner; T Poch
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.